These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 32353006)

  • 1. Generic escitalopram initiation and substitution among Medicare beneficiaries: A new user cohort study.
    Li C; Chen L; Huo N; Mishuk AU; Hansen RA; Harris I; Kiptanui Z; Wang Z; Qian J
    PLoS One; 2020; 15(4):e0232226. PubMed ID: 32353006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient factors associated with oral generic olanzapine initiation and substitution among Medicaid beneficiaries: a new user cohort study.
    Mishuk AU; Chen L; Li C; Huo N; Hansen RA; Harris I; Kiptanui Z; Qian J
    Curr Med Res Opin; 2021 Apr; 37(4):655-664. PubMed ID: 33507825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generic levothyroxine initiation and substitution among Medicare and Medicaid populations: a new user cohort study.
    Huo N; Chen L; Ullah Mishuk A; Li C; Hansen RA; Harris I; Kiptanui Z; Wang Z; Dutcher SK; Qian J
    Endocrine; 2020 May; 68(2):336-348. PubMed ID: 31993992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of costs of Medicare Part D prescriptions dispensed at retail and mail order pharmacies.
    Carroll NV
    J Manag Care Spec Pharm; 2014 Sep; 20(9):959-67. PubMed ID: 25166295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic impact of therapeutic substitution of a brand selective serotonin reuptake inhibitor with an alternative generic selective serotonin reuptake inhibitor in patients with major depressive disorder.
    Wu EQ; Yu AP; Lauzon V; Ramakrishnan K; Marynchenko M; Ben-Hamadi R; Blum S; Erder MH
    Ann Pharmacother; 2011 Apr; 45(4):441-51. PubMed ID: 21415162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of a retrospective claims database analysis of differences in antidepressant treatment persistence associated with escitalopram and other selective serotonin reuptake inhibitors in the United States.
    Esposito D; Wahl P; Daniel G; Stoto MA; Erder MH; Croghan TW
    Clin Ther; 2009 Mar; 31(3):644-56. PubMed ID: 19393855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral generic tacrolimus initiation and substitution in the Medicaid population: a new user cohort study.
    Chen L; Li C; Huo N; Mishuk AU; Hansen RA; Harris I; Kiptanui Z; Qian J
    Curr Med Res Opin; 2020 Sep; 36(9):1533-1540. PubMed ID: 32644886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-Cost Generic Program Use by Medicare Beneficiaries: Implications for Medication Exposure Misclassification in Administrative Claims Data.
    Pauly NJ; Talbert JC; Brown J
    J Manag Care Spec Pharm; 2016 Jun; 22(6):741-51. PubMed ID: 27231801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential savings associated with drug substitution in Medicare Part D: the Translating Research into Action for Diabetes (TRIAD) study.
    Duru OK; Ettner SL; Turk N; Mangione CM; Brown AF; Fu J; Simien L; Tseng CW
    J Gen Intern Med; 2014 Jan; 29(1):230-6. PubMed ID: 23975059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness of generic and brand-name medication use: A database study of US health insurance claims.
    Desai RJ; Sarpatwari A; Dejene S; Khan NF; Lii J; Rogers JR; Dutcher SK; Raofi S; Bohn J; Connolly JG; Fischer MA; Kesselheim AS; Gagne JJ
    PLoS Med; 2019 Mar; 16(3):e1002763. PubMed ID: 30865626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of Bayesian net benefit regression model to examine the impact of generic drug entry on the cost effectiveness of selective serotonin reuptake inhibitors in elderly depressed patients.
    Shih YC; Bekele NB; Xu Y
    Pharmacoeconomics; 2007; 25(10):843-62. PubMed ID: 17887806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generic alendronate use among Medicare beneficiaries: are Part D data complete?
    Yun H; Curtis JR; Saag K; Kilgore M; Muntner P; Smith W; Matthews R; Wright N; Morrisey MA; Delzell E
    Pharmacoepidemiol Drug Saf; 2013 Jan; 22(1):55-63. PubMed ID: 23135758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness of generic versus brand-name antiepileptic medications.
    Gagne JJ; Kesselheim AS; Choudhry NK; Polinski JM; Hutchins D; Matlin OS; Brennan TA; Avorn J; Shrank WH
    Epilepsy Behav; 2015 Nov; 52(Pt A):14-8. PubMed ID: 26386779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generic drug discount programs: are prescriptions being submitted for pharmacy benefit adjudication?
    Tungol A; Starner CI; Gunderson BW; Schafer JA; Qiu Y; Gleason PP
    J Manag Care Pharm; 2012; 18(9):690-700. PubMed ID: 23206212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Healthcare expenditure in severely depressed patients treated with escitalopram, generic SSRIs or venlafaxine in the UK.
    Wade AG; Saragoussi D; Despiégel N; François C; Guelfucci F; Toumi M
    Curr Med Res Opin; 2010 May; 26(5):1161-70. PubMed ID: 20297951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discontinuation rates and health care costs in adult patients starting generic versus brand SSRI or SNRI antidepressants in commercial health plans.
    Vlahiotis A; Devine ST; Eichholz J; Kautzner A
    J Manag Care Pharm; 2011 Mar; 17(2):123-32. PubMed ID: 21348545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in the Use of Brand Name and Generic Medications and Total Prescription Cost Among Medicare Beneficiaries With Epilepsy.
    Terman SW; Lin CC; Kerr WT; DeLott LB; Callaghan BC; Burke JF
    Neurology; 2022 Aug; 99(8):e751-e761. PubMed ID: 35705496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
    Goedken AM; Urmie JM; Farris KB; Doucette WR
    Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Racial and Ethnic Differences in Initiation and Discontinuation of Antidementia Drugs by Medicare Beneficiaries.
    Thorpe CT; Fowler NR; Harrigan K; Zhao X; Kang Y; Hanlon JT; Gellad WF; Schleiden LJ; Thorpe JM
    J Am Geriatr Soc; 2016 Sep; 64(9):1806-14. PubMed ID: 27549029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in Utilization and Cost of Low-Density Lipoprotein Cholesterol-Lowering Therapies Among Medicare Beneficiaries: An Analysis From the Medicare Part D Database.
    Sumarsono A; Lalani HS; Vaduganathan M; Navar AM; Fonarow GC; Das SR; Pandey A
    JAMA Cardiol; 2021 Jan; 6(1):92-96. PubMed ID: 32902560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.